Development and validation of a high-performance clinical predictive model for early identification of non-alcoholic fatty liver disease

开发和验证用于早期识别非酒精性脂肪肝疾病的高性能临床预测模型

阅读:1

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) remains a significant global health challenge, imposing substantial clinical and economic burdens. There is an urgent need to develop reliable predictive tools for early identification and intervention. METHODS: This study drew on Dryad database data to create and verify a clinical NAFLD predictive model, incorporating key parameters from 1,592 subjects randomly split into training and validation groups. We employed logistic regression on the training set to construct the model, visualized and internally validated it in R, and gauged its net benefit via decision curve analysis. The validation set underwent external assessment, with performance metrics including F1 score, precision, and recall. RESULTS: The model showed strong discrimination, with an receiver operating characteristic curve area of 0.80 (95% confidence interval: 0.77-0.82) in training and 0.78 in validation, indicating high accuracy in NAFLD risk prediction. Calibration tests showed close alignment between predicted and actual risks, with mean absolute error values of 0.016 (training) and 0.012 (validation). Comprehensive metrics (F1 score: 0.76, precision: 0.71, recall: 0.82) reinforced its robustness and clinical value. CONCLUSION: This study's results confirm the effective creation of an NAFLD predictive tool boasting high calibration accuracy and outstanding performance. Leveraging readily available clinical data, the model offers a scalable, economical approach to NAFLD, poised to pioneer a new paradigm for its precise prevention and control, and enable personalized prevention and efficient resource allocation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。